Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL-001 in Congenital Erythropoietic Porphyria (CEP)
NCT07024316Phase 2Recruiting
- Sponsor
- Atlas Molecular Pharma
- Start
- Jan 2026
- Primary completion
- May 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ATL-001 in congenital erythropoietic porphyria (CEP), sponsored by Atlas Molecular Pharma. Started Jan 2026; status: recruiting.
02
Drugs
ATL-001
03
Conditions
congenital erythropoietic porphyria (CEP)
Beyond the preview
Go deeper on NCT07024316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024316.